| Bioactivity | Drotrecogin alfa activated (DrotAA) is recombinant human activated protein C (APC). Drotrecogin alfa activated prevents smoke-induced increases in pulmonary microvascular permeability and proinflammatory cytokine IL-1β in rats. Drotrecogin alfa activated inhibits coagulation and inflammation and promotes fibrinolysis. Drotrecogin alfa activated can be used for severe sepsis reaearch[1][2]. |
| In Vivo | Drotrecogin alfa activated (0-20 mg/kg, IV immediately following smoke exposure, once) significantly attenuates smoke inhalation injury in a dose-dependent manner at 2 hours after insult. Drotrecogin alfa activated (20 mg/kg) has an improvement of the expiration phase of pulmonary dynamic compliance[2]. |
| Name | Drotrecogin alfa (activated) |
| CAS | 98530-76-8 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lyseng-Williamson KA, et al. Drotrecogin alfa (activated). Drugs. 2002;62(4):617-30; discussion 631-2. [2]. Wong SS, et al. Drotrecogin alfa (activated) prevents smoke-induced increases in pulmonary microvascular permeability and proinflammatory cytokine IL-1beta in rats. Lung. 2004;182(6):319-30. |